Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dactinomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.83 |
| ▸ | GRB2 | P62993 | 3/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.83 |
| ▸ | CASP1 | P29466 | 1/20 | 0.83 |
| ▸ | HTT | P42858 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | CASP7 | P55210 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.83 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.83 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dactinomycin SCHEMBL2777524 | 0.99 | GRB2 (0.84) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL20771248 | 0.94 | GRB2 (0.74) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL2790145 | 0.92 | GRB2 (0.99) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL3844 | 0.91 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL13659669 | 0.91 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL19770615 | 0.91 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL27304406 | 0.91 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL3845 | 0.91 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL6939686 | 0.91 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL6152 | 0.91 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012047664-A1 | ANTI-PECAM THERAPY, COMPOSITIONS, METHODS, AND USES | SUTTER WEST BAY HOSPITAL D/B/A CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2012-04-12 | — | — | WO | claimed |
| US-20120076795-A1 | Anti-PECAM Therapy, Compositions, Methods, and Uses | Sutter West Bay Hospitals D/B/A California Pacific Medical Center (US) | 2012-03-29 | — | — | US | claimed |
| WO-2007092432-A2 | LIQUID-FILLED NANODROPLETS FOR ANTI-CANCER THERAPY | IMARX THERAPEUTICS, INC. (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070184076-A1 | Liquid-filled nanodroplets for anti-cancer therapy | IMA RY THERAPEUTICS, INC. | 2007-08-09 | — | — | US | claimed |
| US-20030198664-A1 | Lipid mediated screening of drug candidates for identification of active compounds | FLORIDA, UNIVERSITY OF | 2003-10-23 | — | — | US | claimed |
| WO-2003083443-A2 | LIPID MEDIATED SCREENING OF DRUG CANDIDATES FOR IDENTIFICATION OF ACTIVE COMPOUNDS | UNIVERSITY OF FLORIDA (US) | 2003-10-09 | — | — | WO | claimed |
| US-5770222-A | Therapeutic drug delivery systems | IMARX PHARMACEUTICAL CORP. (US) | 1998-06-23 | — | — | US | claimed |
| EP-3436049-B1 | ANGIOPOIETIN-LIKE PROTEIN 8 (ANGPTL8) | BAYLOR RES INSTITUTE (US) | 2022-01-12 | — | — | EP | disclosed |
| US-11116788-B2 | Compositions comprising sulfated polysaccharides and uses thereof | ALGAMED THERAPEUTICS (A.M.T) LTD (IL) | 2021-09-14 | — | — | US | disclosed |
| US-10947275-B2 | Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2021-03-16 | — | — | US | disclosed |
| US-20200368358-A1 | DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-11-26 | — | — | US | disclosed |
| US-10736965-B2 | Risperidone biodegradable implant | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200179520-A1 | COMPOSITIONS AND METHODS FOR TARGETED TREATMENT AND IMAGING OF CANCER OR TUMORS | WASHINGTON UNIVERSITY | 2020-06-11 | — | — | US | disclosed |
| EP-0712293-A1 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER, Evan C (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0711127-A1 | METHODS OF PREPARING GAS-FILLED LIPOSOMES | UNGER, Evan C (US) | 1996-05-15 | — | — | EP | disclosed |
| EP-0707471-A1 | NOVEL THERAPEUTIC DRUG DELIVERY SYSTEMS | IMARX PHARMACEUTICAL CORP. (US) | 1996-04-24 | — | — | EP | disclosed |
| US-5469854-A | Methods of preparing gas-filled liposomes | IMARX PHARMACEUTICAL CORP. (US) | 1995-11-28 | — | — | US | disclosed |
| WO-1994028780-A2 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994028797-A1 | METHODS OF PREPARING GAS-FILLED LIPOSOMES | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994028873-A1 | NOVEL THERAPEUTIC DRUG DELIVERY SYSTEMS | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947275-B2 | Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications | LNPEP, PRCP, CLSPN | PTGS1 4477/4885GRB2 3107/4885MAPT 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.